Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$14.16 +1.49%

+$0.37 today

Market cap
$1.25B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.17M

Average 1.48M

Returns on capital

Mineralys Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-23.9%

avg 15.0%

ROIC

-26.4%

avg -137.7%

ROA

-23.4%

avg -94.9%

Analysis

ROA is currently the strongest return metric at -23.4% versus its period average of -94.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jon Congleton

President, Chief Executive Officer & DirectorUSD 1.11M63528.62K0.80%

James J. Ferguson FACC

Chief Medical OfficerUSD 881.8K72——

Adam Scott Levy

Chief Financial Officer & SecretaryUSD 880.19K4848.54K0.07%

Brian Taylor Slingsby

Founder & Executive DirectorUSD 78K497.81M11.77%

Eric J. Warren

Chief Commercial Officer—54——

Jeffrey A. Munsie

Chief Legal Officer—49——

Michael Tortorici

Senior Vice President of Translational Medicine————

Danielle Mahoney

Senior Vice President of Quality Assurance————

Robert McKean

Senior Vice President of CMC————

Jessica Ibbitson

Executive Vice President of Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$8.76M

Sells

56

$27.84M

Net Transaction Value

−$19.08M

Net selling

Most Active

Rodman David Malcom

37 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 30, 26

Congleton Jon

Direct

Sell$1.9M
Sep 22, 26

Slingsby Brian Taylor

Indirect

Sell$3M
Sep 21, 26

Warren Eric

Direct

Sell$209.1K
Sep 15, 26

Karydas Daphne

Direct

Sell$85.7K
Aug 21, 26

Warren Eric

Direct

Sell$193.2K
Aug 10, 26

Rodman David Malcom

Direct

Sell$58.8K
Jul 21, 26

Warren Eric

Direct

Sell$199.9K
Jul 17, 26

Rodman David Malcom

Direct

Sell$11K
Jul 15, 26

Rodman David Malcom

Direct

Sell$169K
Jul 13, 26

Rodman David Malcom

Direct

Sell$387.7K

1–10 of 58

Summary

Insiders reported 2 buys worth $8.76M and 56 sells worth $27.84M over the last 12 months. That adds up to net selling of $19.08M. Rodman David Malcom was the most active insider with 37 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Mineralys Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MLYS's management, answered from reported figures.

Who manages MLYS?

Mineralys Therapeutics, Inc. (MLYS) lists 10 active executives. The top listed executive is James J. Ferguson FACC, Chief Medical Officer.

Are MLYS insiders buying or selling?

Recent insider activity shows net selling of $4.85M.